Material Event Form 8 K

Item 5.07 Submission of Matters to a Vote of Security Holders

ENDRA Life Sciences (the "Company") held a Special Meeting of Stockholders (the "Special Meeting") on October 28, 2024. The certified results of the matter voted upon at the Special Meeting, which is more fully described in the definitive proxy statement for the Special Meeting as filed with the Securities and Exchange Commission on September 16, 2024, are as follows:

Proposal 1 - The Company's stockholders approved amendments to the Company's Fourth Amended and Restated Certificate of Incorporation effecting reverse stock splits of its common stock at ratios between 1-for-4 and 1-for-35, inclusive, one of which reverse stock split ratios will be chosen, at the discretion of our Board of Directors on or prior to the one-year anniversary of the date of the Special Meeting, and the remainder of which reverse stock split ratios will be abandoned (the "Reverse Stock Split"):